Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq set to open higher as CPI, bank earnings take focus; IBM tumbles
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Morgan Stanley Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
January 27, 2025 12:54 PM ESTMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $200.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "Updated results from the pivotal EMBARK study, demonstrated consistent and durable benefits in patients switched to Elevidys (Part 2, crossover) and those two years... More
